Revenio Group Corporation, Press release, October 13, 2022 at 9.00 a.m. (EEST)
Revenio Group Corporation’s January-September 2022 Interim Report will be published on Thursday, October 27, 2022, approximately at 09.00 a.m. (EEST). The report will be available at https://www.reveniogroup.fi/en/investors/reports_and_presentations
An audiocast and conference call for analysts and investors will be held in English at 3.00 p.m. (EEST) on the same day.
Link to the event: https://revenio.videosync.fi/q3-2022-results
Dial in numbers for the conference call:
Finland Local Helsinki: +358 9 2319 5436
Standard International Access UK-Wide: +44 (0) 33 0551 0211
Sweden Local Stockholm: +46 (0) 8 5051 0086
UK Local UK-Wide: +44 (0) 33 0551 0202
USA Local Atlanta: +1 678 805 0961
USA Local New York: +1 646 843 4609
PIN: 0939951#
For further information, please contact
Robin Pulkkinen, CFO, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi
Distribution
Key media
www.revenio.fi/en
Revenio Group in brief
Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.
In 2021, the Group’s net sales totaled EUR 78.8 million, with an operating profit of EUR 22.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.